Investigations on gossypol: past and present developments.

abstract：:Despite advances in supportive care, septic shock remains a major cause of morbidity and mortality. With the identification of the systemic inflammatory response as a major component in the pathogenesis of the septic shock syndrome, much of the recent work has focused on modulating this response. This includes antiend...

journal_title：Expert opinion on investigational drugs

authors： Sharma VK,Dellinger RP

更新日期：2003-02-01 00:00:00

abstract：INTRODUCTION:Angiogenesis inhibition represents a rational therapeutic strategy in the management of solid tumors. Brivanib is a dual tyrosine kinase inhibitor with selectivity against VEFGR-2 and FGFR. AREAS COVERED:This review provides an updated summary of preclinical and clinical experience with brivanib in cancer...

journal_title：Expert opinion on investigational drugs

authors： Diaz-Padilla I,Siu LL

更新日期：2011-04-01 00:00:00

abstract：:Endothelin (ET) is a pivotal physiological regulator of blood pressure through its effects on blood vessels, heart, lung and kidneys, and the ET system can be overactive in disorders such as pulmonary hypertension, heart failure and renal disease. Such observations stimulated interest among scientists and pharmaceutic...

journal_title：Expert opinion on investigational drugs

authors： Benigni A,Perico N,Remuzzi G

更新日期：2004-11-01 00:00:00

abstract：INTRODUCTION:In the last decade, concerns have been raised around the use of erythropoiesis-stimulating agents (ESAs) and intravenous iron in chronic kidney disease (CKD) patients, especially when given at high doses. Moreover, treatment with ESA is expensive. AREAS COVERED:We searched PubMed for original articles, re...

journal_title：Expert opinion on investigational drugs

authors： Del Vecchio L,Locatelli F

更新日期：2018-07-01 00:00:00

abstract：BACKGROUND:Even established and effective antiarrhythmic drugs (AADs) in atrial fibrillation (AF) are limited by their pro-arrhythmic and non-target organ side effects. Therefore the search continues for safer and effective new AADs. OBJECTIVE:This review will examine a novel AAD, tedisamil--a multichannel potassium c...

journal_title：Expert opinion on investigational drugs

authors： Krishnamoorthy S,Lip GY

更新日期：2009-08-01 00:00:00

abstract：:The discovery of new antibacterial drugs can be based either upon empirical screening methods or structure-based design. Empirical methods utilise both intact bacteria and isolated biochemical targets for high throughput screening of natural product or chemical libraries to detect inhibitor leads. Structure-based meth...

journal_title：Expert opinion on investigational drugs

authors： Chopra I

更新日期：1997-08-01 00:00:00

abstract：:The role of nerve growth factor in stimulating cholinergic function, loss of which is a cardinal feature in Alzheimer's disease, has been documented for many years from preclinical animal model studies. This anabolic growth factor has been delivered into the forebrain of patients with mild Alzheimer's disease using tr...

journal_title：Expert opinion on investigational drugs

authors： Braddock M

更新日期：2005-07-01 00:00:00

abstract：:COPD is a chronic disease of the lung that is characterised by decreased air flow and associated abnormal inflammatory responses of the lungs. A total of 80% of COPD incidences are observed in patients with history of smoking tobacco. The chronic condition of COPD is characterised by airway remodelling, which leads to...

journal_title：Expert opinion on investigational drugs

authors： Srivastava PK,Dastidar SG,Ray A

更新日期：2007-07-01 00:00:00

abstract：INTRODUCTION:Patients with myelofibrosis (MF) have no effective treatment option after the failure of approved JAK inhibitor (JAKi) therapy. Non-JAK inhibitors (non-JAKi) that target non-canonical molecular pathways are undergoing clinical evaluations to optimize efficacy and/or to reduce hematological toxicity of JAKi...

journal_title：Expert opinion on investigational drugs

authors： Bankar A,Gupta V

更新日期：2020-05-01 00:00:00

abstract：INTRODUCTION:Stroke is the second leading cause of death worldwide and the leading cause of adult neurological disability. Despite advances in stroke unit care, and increasing use of thrombolysis, there remains an urgent need for safe and effective treatments for acute ischaemic stroke. However, this is against a backd...

journal_title：Expert opinion on investigational drugs

authors： Smith CJ,Denes A,Tyrrell PJ,Di Napoli M

更新日期：2015-05-01 00:00:00

abstract：INTRODUCTION:Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). Here, the authors review the pharmacology of the drug, and offer critical review of the available data for...

journal_title：Expert opinion on investigational drugs

authors： Bickston SJ,Snider KR,Kappus MR

更新日期：2012-12-01 00:00:00

abstract：:This paper gives an overview of the available pharmacological and clinical data of a new class of anticancer drugs which act by binding DNA in the minor groove, comprising cyclopropylpyrrolo-indole (CC-1065) derivatives and Distamycin derivatives. The emphasis of this review is placed on the distinctive mode of action...

journal_title：Expert opinion on investigational drugs

authors： D'Incalci M,Sessa C

更新日期：1997-07-01 00:00:00

abstract：:The focus of this meeting was the interface between eating disorders and obesity. A symposium at this meeting dealt with advances in treatment for bulimia nervosa (BN) and binge eating disorder. There were two presentations in this symposium that addressed pharmacological treatments. One reviewed drug treatments for B...

journal_title：Expert opinion on investigational drugs

authors： Kaplan AS

更新日期：2003-08-01 00:00:00

abstract：:'Male factor' problems contribute to subfertility in a significant proportion of couples. In some instances, defective sperm production has qualitative and/or quantitative effects on the semen profile; in others, no obvious defects can be detected, yet spermatozoa are non-fertilising. Recent studies have revealed that...

journal_title：Expert opinion on investigational drugs

authors： Fraser LR

更新日期：1997-12-01 00:00:00

abstract：:CGRP is a potent vasodilator that has been shown to have a physiological and/or pathological role in neurogenic inflammation, headaches including migraine, thermal injury, circulatory shock, pregnancy and menopause, hypertension and heart failure and is known to be cardioprotective. CGRP is also a positive inotrope an...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2001-06-01 00:00:00

abstract：:Recent advances in the treatment and management of haematological malignancies are due in large part to an improved understanding of the basic biology that drives tumour cell growth and survival. This improved understanding has led to the clinical study and approval of a number of different targeted agents across a nu...

journal_title：Expert opinion on investigational drugs

authors： Haas M,Lonial S

更新日期：2005-09-01 00:00:00

abstract：:Currently available antifungal drugs for serious infections are either fungistatic and vulnerable to resistance (azoles) or fungicidal but toxic to the host (polyenes). Cell wall-acting antifungals are inherently selective and fungicidal, features that make them particularly attractive for clinical development. Three ...

journal_title：Expert opinion on investigational drugs

authors： Georgopapadakou NH

更新日期：2001-02-01 00:00:00

abstract：:This review highlights some important advances that have taken place in cannabinoid research over the last four years. It focuses on novel ligands that are of interest either as experimental tools or as lead compounds for therapeutic agents and possible clinical applications for some of these ligands. The molecular ta...

journal_title：Expert opinion on investigational drugs

authors： Pertwee RG

更新日期：2000-07-01 00:00:00

abstract：:With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non-Hodgkin's-lymphomas (NHL) has gained momentum. Since the first description of the CD20 mAb and its use in a single patient, it has taken more than 20 years to implement this in current t...

journal_title：Expert opinion on investigational drugs

authors： Schultze JL

更新日期：1999-12-01 00:00:00

abstract：:Venous and arterial thromboembolism are a major cause for morbidity and mortality. The list of established drugs for the prevention of thrombus formation and embolisation includes heparins, hirudin and derivatives, aspirin, ADP and glycoprotein IIb/IIIa receptor antagonists, as well as vitamin K antagonists. Several l...

journal_title：Expert opinion on investigational drugs

authors： Ruef J,Katus HA

更新日期：2003-05-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Contrasting with the broad activation of the PI3K/AKT/mammalian target of rapamycin (mTOR) survival pathway in most cancer, activity of rapalogues appears to be restricted to a few tumor types. AREAS COVERED IN THIS REVIEW:The analysis of molecular activity of the PI3K/AKT/mTOR pathway and resi...

journal_title：Expert opinion on investigational drugs

authors： Albert S,Serova M,Dreyer C,Sablin MP,Faivre S,Raymond E

更新日期：2010-08-01 00:00:00

abstract：INTRODUCTION:Relapsed/refractory multiple myeloma (rrMM) remains a difficult condition to treat despite the availability of new drugs. This review aims to provide evidence to guide physicians in the choice of salvage therapy in certain subgroups of patients. AREAS COVERED:The review attempts to present evidence-based ...

journal_title：Expert opinion on investigational drugs

authors： Offidani M,Corvatta L,Morabito F,Gentile M,Musto P,Leoni P,Palumbo A

更新日期：2011-06-01 00:00:00

abstract：INTRODUCTION:Epidermal growth factor receptor (EGFR) targeted treatment has been evaluated but has not shown a clear clinical benefit for breast cancer. This review article aims to consider the knowledge of the biological background of EGFR pathways in dissecting clinical studies of EGFR targeted treatment in breast ca...

journal_title：Expert opinion on investigational drugs

authors： Matsuda N,Lim B,Wang X,Ueno NT

更新日期：2017-04-01 00:00:00

abstract：:Leukotriene B(4) (LTB(4)) is a lipid inflammatory mediator derived from membrane phospholipids by the sequential actions of cytosolic phospholipase A2 (PLA2), 5-lipoxygenase (5-LO) and leukotriene A(4) (LTA(4)) hydrolase. Several inflammatory diseases, including asthma, chronic obstructive pulmonary disease, arthritis...

journal_title：Expert opinion on investigational drugs

authors： Hicks A,Monkarsh SP,Hoffman AF,Goodnow R Jr

更新日期：2007-12-01 00:00:00

abstract：:Interstitial cystitis (IC) is a painful, sterile, disorder of the urinary bladder characterised by urgency, frequency, nocturia and pain. IC occurs primarily in women but also in men with recent findings indicating that chronic, abacterial prostatitis may be a variant of this condition. The prevalence of IC has ranged...

journal_title：Expert opinion on investigational drugs

authors： Theoharides TC,Sant GR

更新日期：2001-03-01 00:00:00

abstract：:Increasing evidence suggests an important role for autocrine/paracrine prolactin in breast and prostate cancers and other disease states. Prolactin production in these extrapituitary sites is not governed by dopamine agonists, a finding that has spurred the production of prolactin receptor antagonists. This review foc...

journal_title：Expert opinion on investigational drugs

authors： Walker AM

更新日期：2006-10-01 00:00:00

abstract：INTRODUCTION:Gut-specific homing is mainly mediated by the expression of MAdCAM-1 on endothelial cells. An increase in MAdCAM-1 expression has been shown in patients with inflammatory bowel disease (IBD). Areas covered: PF-00547659 is a fully human monoclonal antibody (mAb) toward MAdCAM-1 on endothelial cells, blockin...

journal_title：Expert opinion on investigational drugs

authors： Allocca M,Gilardi D,Fiorino G,Furfaro F,Argollo M,Peyrin-Biroulet L,Danese S

更新日期：2018-07-01 00:00:00

abstract：:Olpadronate is a nitrogenated bisphosphonate. Although it shares the therapeutic and pharmacological properties of pamidronate and alendronate, it has a greater dosage amplitude, more predictable effects and a greater digestive tolerability than other bisphosphates. Therefore, it may be more appropriate in the treatme...

journal_title：Expert opinion on investigational drugs

authors： Roldán EJ,Pérez-Llore A,Ferretti JL

更新日期：1998-09-01 00:00:00

abstract：:Poly (ADP-ribose) polymerase (PARP) plays a key role in DNA repair mechanisms by detecting and initiating repair after DNA strand breaks. Inhibition of PARP in DNA repair-defective tumors (like those with BRCA1 or BRCA2 mutations) can lead to gross genomic instability and cell death. Likewise, combining PARP inhibitio...

journal_title：Expert opinion on investigational drugs

authors： Rodon J,Iniesta MD,Papadopoulos K

更新日期：2009-01-01 00:00:00

abstract：:Presentations at the William Harvey Research Conference on PDE Inhibitors described the molecular biology, biochemical regulation. pharmacology, and therapeutic utility of inhibitors of cyclic nucleotide phosphodiesterases (PDEs). Most of the talks focused on PDE4 and PDE5. two members of the 11-member PDE family that...

journal_title：Expert opinion on investigational drugs

authors： O'Donnell

更新日期：2000-03-01 00:00:00